Current systemic therapeutic options for advanced mycosis fungoides and Sézary syndrome. Issue 3 (4th March 2018)

• Record Type: Journal Article
• Authors: Janiga, Jenna; Kentley, Jonathan; Nabhan, Chadi; Abdulla, Farah
• Is Part Of: Leukemia & lymphoma. Volume 59:Issue 3(2018)
• Page Start: 562
• Page End: 577
• Publication Date: 2018-03-04
• Subjects: Mycosis fungoides -- Sézary syndrome -- CTCL -- management -- treatment; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2017.1347650
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: Mycosis fungoides (MF) and Sézary syndrome (SS) are the most common cutaneous T-cell lymphomas (CTCLs). Both lack curative options, and advanced-stage carries a poor prognosis. Whilst there are a number of treatments available, achieving and maintaining a durable remission remains challenging. We review current systemic treatment options as monotherapy for advanced-stage MF (IIB–IV), appraising their mechanism of action, analyzing their efficacy, and describing toxicities. Individually, reported overall response rates (ORR) vary widely in the literature and duration of responses are typically short, ranging from 7.5 to 22.4 months. Combined therapy is frequently used in an effort to boost responses, although prospective studies comparing combinations to single agent therapies are rarely conducted. While recent translational research has led to increased understanding of the immunopathogenesis of MF and SS and the development of new treatments, current standard of care therapies are not curative and have low ORR for advanced-stage disease.